UK markets closed

Akebia Therapeutics, Inc. (AKBA)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.3500-0.0100 (-0.74%)
At close: 04:00PM EDT
1.3700 +0.02 (+1.48%)
After hours: 07:57PM EDT

Akebia Therapeutics, Inc.

245 First Street
Suite 1400
Cambridge, MA 02142
United States
617 871 2098

Full-time employees167

Key executives

NameTitlePayExercisedYear born
Mr. John P. Butler MBACEO, President & Director1.81MN/A1964
Dr. Steven Keith Burke M.D.Senior VP of Research & Development and Chief Medical Officer937.39kN/A1961
Mr. Erik John Ostrowski M.B.A.Chief Financial Officer, Senior Vice President & Chief Business OfficerN/AN/A1972
Mr. Richard C. MalabreChief Accounting OfficerN/AN/A1961
Ms. Kimberly GarkoSenior VP & Chief Technical OfficerN/AN/AN/A
Ms. Tracey VetterickVice President of Portfolio Strategy & Corporate AdministrationN/AN/AN/A
Mercedes CarrascoSenior Director of Investor & Corporate CommunicationsN/AN/AN/A
Ms. Carolyn RucciSenior VP of Legal & General CounselN/AN/AN/A
Ms. Meredith BowmanSenior VP & Chief People OfficerN/AN/AN/A
Mr. Nicholas GrundSenior VP & Chief Commercial OfficerN/AN/A1970
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Corporate governance

Akebia Therapeutics, Inc.’s ISS governance QualityScore as of 1 July 2024 is 9. The pillar scores are Audit: 10; Board: 5; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.